Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Scotland

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

Amgen agrees to lower prescription drug costs in deal with US government

The company has invested $40bn in US R&D and manufacturing in the past seven years

- PMLiVE

Amgen reports positive results from landmark cardiovascular study

The study found significant reductions of major cardiovascular events in high-risk adults following treatment

- PMLiVE

Novo Nordisk agrees to lower certain drug prices in the US

The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

- PMLiVE

Lilly announces agreement with US government to lower patient costs

The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

- PMLiVE

ViiV Healthcare receives NICE recommendation for HIV prevention therapy

The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

- PMLiVE

Pfizer’s Lorviqua recommended by NICE for lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide

- PMLiVE

Amgen commits $650m to US manufacturing expansion

The investment is expected to generate up to 750 new jobs

- PMLiVE

Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

The phase 3 study included around 2,600 patients

- PMLiVE

Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

Approximately 38.4 million people in the US are affected by diabetes

- PMLiVE

NICE recommends ALK’s immunotherapy to target underlying cause of hay fever

An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax

- PMLiVE

NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links